Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo
- 1 December 2014
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 196, 113-121
- https://doi.org/10.1016/j.jconrel.2014.10.005
Abstract
No abstract availableFunding Information
- Leukemia Research Foundation
This publication has 34 references indexed in Scilit:
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple MyelomaClinical Cancer Research, 2013
- Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivoBlood Cancer Journal, 2012
- Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myelomaCore Evidence, 2011
- Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacyProceedings of the National Academy of Sciences of the United States of America, 2010
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasomeBlood, 2009
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the ProteasomeCancer Research, 2007
- Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood, 2003
- Molecular mechanisms of novel therapeutic approaches for multiple myelomaNature Reviews Cancer, 2002